Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1
– Oveporexton was Generally Well-Tolerated in Phase 3 Safety Profile
– Takeda is Rapidly Advancing Regulatory Submissions and Launch Preparedness with the Aim to Bring Oveporexton to People Living with Narcolepsy Type 1 as Quickly as Possible
– These Results Mark a Major Advancement Toward Transforming the Standard of Care by Addressing the Underlying Cause of Narcolepsy Type 1
OSAKA, Japan & CAMBRIDGE, Mass., July 14, 2025--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that all primary and secondary endpoints were met in two Phase 3 randomized, double-blind, placebo-controlled studies of oveporexton (TAK-861), a potential first-in-class investigational oral orexin receptor 2 (OX2R)-selective agonist, in narcolepsy type 1 (NT1). NT1 is caused by the loss of orexin-producing neurons in the brain. Orexin agonists are designed to address this underlying orexin deficiency. For the first time, this mechanism of action has been validated in Phase 3 studies demonstrating significant improvement across a broad range of symptoms. These results reinforce the potential of oveporexton to transform the standard of care.
"We are thrilled to reach this pivotal milestone for the oveporexton program. Oveporexton is a testament to Takeda's strength in discovering and developing a potential new class of medicines for difficult to treat diseases such as narcolepsy type 1," said Christophe Weber, president and chief executive officer at Takeda. "Our leadership in orexin biology and building a multi-asset orexin franchise with transformative potential will position Takeda for long-term future growth."
The FirstLight (TAK-861-3001) and RadiantLight (TAK-861-3002) studies were two large, global Phase 3 studies conducted in 19 countries. Both studies achieved statistically significant improvement compared to placebo with p-values of <0.001 for all primary and secondary endpoints across all doses at week 12. The primary and secondary endpoints measuring objective and patient reported improvements in wakefulness, excessive daytime sleepiness, cataplexy, ability to maintain attention, overall quality of life and daily life functions demonstrate statistically significant and clinically meaningful improvements achieving near normal ranges across the broad range of symptoms investigated.
Oveporexton was generally well-tolerated with a safety profile from the Phase 3 studies overall consistent with oveporexton studies to date including the Phase 2b study. No serious treatment-related adverse events were reported. The most common adverse events were insomnia, urinary urgency and frequency. More than 95 percent of the participants who completed the studies enrolled in the ongoing long-term extension (LTE) study.
"We are grateful to the patients who took part in these clinical studies and to their families, the investigators and clinical staff. The studies were accelerated at an unprecedented pace with the aim to bring this potential treatment to people living with narcolepsy type 1 as quickly as possible," said Andy Plump, M.D., Ph.D., president of R&D at Takeda. "The comprehensive assessments from our Phase 3 studies build on the transformative results we saw with our Phase 2b study with most participants reaching normative ranges and reporting clinically meaningful improvement across a broad range of symptoms at the end of the 12-week treatment period. The positive results also reinforce the continued momentum for our late-stage pipeline, which we believe will deliver value to the patients we serve around the world."
Takeda intends to present the results at upcoming medical congresses and plans to submit a New Drug Application with the United States Food and Drug Administration and additional global regulatory authorities in fiscal year 2025.
Results from the Phase 3 studies have no significant impact on the full year consolidated forecast for the fiscal year ending March 31, 2026.
About Narcolepsy Type 1 (NT1) and Orexin Science
NT1 is a chronic, rare neurological disease that results in a range of debilitating symptoms including excessive daytime sleepiness (EDS), cataplexy, disrupted nighttime sleep, sleep paralysis and hallucinations upon falling asleep or waking. Additionally, individuals living with NT1 often report cognitive symptoms, including difficulty thinking clearly, remembering, concentrating and paying attention. NT1 is caused by loss of the orexin-producing neurons in the brain, which regulate wakefulness and sleep, and is also believed to be essential to other functions such as attention through activation of orexin receptors. Currently, the standard of care is limited to symptomatic therapies that may only partially address some of the symptoms people face.
About Oveporexton (TAK-861)
Oveporexton (TAK-861) is an investigational orexin receptor 2 (OX2R)-selective agonist, which selectively stimulates the OX2R to restore signaling and address the underlying orexin deficiency that causes narcolepsy type 1 (NT1). By activating OX2Rs, oveporexton is designed to promote wakefulness and reduce abnormal rapid eye movement (REM)-sleep like phenomena, including cataplexy, to address the broad spectrum of daytime and nighttime symptoms.
About the FirstLight and RadiantLight Phase 3 Studies
FirstLight (TAK-861-3001; NCT06470828) and RadiantLight (TAK-861-3002; NCT06505031) are global, multicenter, placebo-controlled studies to evaluate the efficacy, safety and tolerability of oveporexton compared to placebo in patients with narcolepsy type 1 (NT1) over 12 weeks. The studies were conducted in 19 countries with enrollment completed within six months. The FirstLight study enrolled 168 participants randomized to one of three dosing arms (high dose, low dose and placebo). The RadiantLight study enrolled 105 participants randomized to two dosing arms (high dose and placebo). The primary endpoint in both studies was improvement in excessive daytime sleepiness (EDS) as measured by the Maintenance of Wakefulness Test (MWT), a standard measure of wakefulness. Key secondary endpoints included improvement in EDS as measured by the Epworth Sleepiness Scale (ESS) and in the Weekly Cataplexy Rate (WCR), a measure evaluating cataplexy. The studies also evaluated the effect of oveporexton on participants' ability to maintain attention, participants' overall quality of life, the spectrum of narcolepsy symptoms and daily life functions, as well as the safety and tolerability of oveporexton.
About Takeda's Orexin Agonists for Sleep-Wake Disorders
Takeda is leading the field of orexin science with a multi-asset franchise. Orexin is a key regulator of sleep and wake patterns and contributes to other essential functions including attention, mood, metabolism and respiration. Oveporexton (TAK-861) is the lead investigational orexin receptor 2 (OX2R) agonist asset in Takeda's orexin franchise and received Breakthrough Therapy designation for the treatment of excessive daytime sleepiness in narcolepsy type 1 (NT1) from the U.S. Food and Drug Administration and the Center for Drug Evaluation of China's National Medical Products Administration. The company is also investigating other orexin agonists in populations with orexin levels in the normal range, including TAK-360, an oral OX2R agonist initially being investigated for the treatment of narcolepsy type 2 (NT2), idiopathic hypersomnia (IH), and other potential indications where orexin signaling is implicated.
About Takeda
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.
Important Notice
For the purposes of this notice, "press release" means this document, any oral presentation, any question-and-answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ("Takeda") regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.
The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, "Takeda" is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words "we", "us" and "our" are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
Forward-Looking Statements
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as "targets", "plans", "believes", "hopes", "continues", "expects", "aims", "intends", "ensures", "will", "may", "should", "would", "could", "anticipates", "estimates", "projects", "forecasts", "outlook" or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda's global business, including general economic conditions in Japan and the United States and with respect to international trade relations; competitive pressures and developments; changes to applicable laws and regulations, including tax, tariff and other trade-related rules; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals; the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits; and other factors identified in Takeda's most recent Annual Report on Form 20-F and Takeda's other reports filed with the U.S. Securities and Exchange Commission, available on Takeda's website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda's future results.
Medical Information
This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250714054710/en/
Contacts
Japanese MediaYuko Yoneyamayuko.yoneyama@takeda.com
U.S. and International MediaRachel Wallacerachel.wallace2@takeda.com
擷取數據時發生錯誤
登入存取你的投資組合
擷取數據時發生錯誤
擷取數據時發生錯誤
擷取數據時發生錯誤
擷取數據時發生錯誤
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
FDA Confirms One Dead After Massive Egg Recall
After the U.S. Food and Drug Administration recalled over 1.7 million "brown cage-free eggs and brown certified organic eggs" throughout the country, the CDC has reported one death in California. The recall occurred in June 2025 due to the risk of Salmonella infection. Per the FDA, the illness occurs within 12 to 72 hours after eating contaminated food, with symptoms lasting between four and seven days. Children, elderly, and the immunocompromised carry the biggest risk of severe reactions. Symptoms include fever, diarrhea, and stomach outbreak spanned ten states and 134 people were confirmed to have been infected, resulting in 38 hospitalizations. The CDC declared that the outbreak has ended. At the time Men's Journal originally reported on the recall, 21 people had been hospitalized with no confirmed deaths. The FDA updated the initial recall statement on July 10. At this point, all recalled eggs from August Egg Company have passed their expiration date and should not be on shelves. The company noted that this was a "voluntary recall" because Salmonella enteritidis "poses a health risk." RELATED: "It is important to know that when our processing plant identified this concern, we immediately began diverting all eggs from the plant to an egg-breaking facility, which pasteurizes the eggs and kills any pathogens," August Egg Company said in a statement on June 6. "August Egg Company's internal food safety team also is conducting its own stringent review to identify what measures can be established to prevent this situation from recurring." The recall had spread to the states of Arizona, California, Colorado, Kansas, Kentucky, Nebraska, New Jersey, Nevada, Utah, and Washington. There have been a slew of food recalls lately, as the FDA recently pulled chocolate products, water bottles sold at Walmart, and more than 367,000 pounds of Oscar Mayer turkey bacon off of Confirms One Dead After Massive Egg Recall first appeared on Men's Journal on Jul 12, 2025
Yahoo
32 minutes ago
- Yahoo
U.S. inflation may have worsened last month as Trump's tariffs start to bite
WASHINGTON (AP) — Inflation likely accelerated in June as sweeping tariffs on nearly all imports may have pushed up prices for electronics, appliances, and other goods, economists forecast. Consumer prices probably rose 2.6% last month from a year ago, up from an annual increase of 2.4% in May, according to data provider FactSet. The Labor Department will issue its inflation report at 8:30 a.m. eastern. On a monthly basis, prices likely rose 0.3% from May to June, the largest increase since January, economists project. Worsening inflation could pose a political challenge for President Donald Trump, who promised during last year's presidential campaign to immediately lower costs. The sharp inflation spike of 2022-2023 was the worst in four decades and soured most Americans on former president Joe Biden's handling of the economy. Faster price increases would also likely underscore the Federal Reserve's reluctance to cut its short-term interest rate, as Trump is loudly demanding. Excluding the volatile food and energy categories, inflation is forecast to have risen 3% in June from a year earlier, up from a 2.8% rise in May. On a monthly basis, it is also expected to have picked up 0.3% from May to June, according to FactSet. Economists closely watch core prices because they typically provide a better sense of where inflation is headed. Trump has imposed sweeping duties of 10% on all imports, plus 50% levies on steel and aluminum, 30% on goods from China, and 25% on imported cars. Just last week the president threatened to hit the European Union with a new 30% tariff starting Aug. 1. So far, the tariffs haven't noticeably pushed up inflation, which has been mild for the past four months. Core inflation has fallen from 3.3% in January to 2.8% in May, though that is still above the Fed's 2% target. If inflation in June is much weaker than economists forecast, Trump will likely renew his demands that Federal Reserve Chair Jerome Powell immediately reduce borrowing costs. Powell and other Fed officials have emphasized that they want to see how the economy evolves as the tariffs take effect before cutting their key short-term rate. The Fed chair has said that the duties could both push up prices and slow the economy, a tricky combination for the central bank since higher costs would typically lead the Fed to hike rates while a weaker economy often spurs it to reduce them. Trump on Monday said that Powell has been 'terrible' and 'doesn't know what the hell he's doing.' The president added that the economy was doing well despite Powell's refusal to reduce rates, but it would be 'nice' if there were rate cuts 'because people would be able to buy housing a lot easier.' Last week, White House officials also attacked Powell for cost overruns on the years-long renovation of two Fed buildings, which are now slated to cost $2.5 billion, roughly one-third more than originally budgeted. While Trump legally can't fire Powell just because he disagrees with his interest rate decisions, the Supreme Court has signaled, he may be able to do so 'for cause,' such as misconduct or mismanagement. While inflation was mild in May, there were already signs in last month's report that tariffs were starting to have some impact. The cost of furniture, appliances, toys, and tools rose, though those increases were offset by falling prices for airfares, hotels, and muted rises in rental costs. Some companies have said they have or plan to raise prices as a result of the tariffs, including Walmart, the world's largest retailer. Automaker Mitsubishi said last month that it was lifting prices by an average of 2.1% in response to the duties, and Nike has said it would implement 'surgical' price hikes to offset tariff costs. But many companies have been able to postpone or avoid price increases, after building up their stockpiles of goods this spring to get ahead of the duties. Other companies may have refrained from lifting prices while they wait to see whether the U.S. is able to reach trade deals with other countries that lower the duties. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
32 minutes ago
- Yahoo
Veteran trader has surprising message on stocks
Veteran trader has surprising message on stocks originally appeared on TheStreet. The stock market's move higher since April 9 has been impressive. The rally has been relentless after President Donald Trump paused most of the reciprocal tariffs he had announced only days earlier on April 2, so-called Liberation Day. The S&P 500 has risen over 25% and the Nasdaq Composite has increased by 35%, with each recently notching all-time highs. 💰Don't miss the move: Subscribe to TheStreet's free daily newsletter💰 The stock market's move in speed and size likely surprised many, given that higher-than-expected tariffs had caused the S&P 500 to tumble 19%, nearly into bear market territory. Many concerns during stocks' sell-off, including the risk of stagflation or recession, remain possibilities, given that unemployment has risen this past year and sticky inflation could ding GDP later this year when the full impact of remaining tariffs passes through supply chains. Stocks generally do best when investors are optimistic about future revenue and earnings growth, and households and businesses ramp up spending rather than retrench. As a result, many people are likely scratching their heads, wondering what may happen next, especially since the S&P 500's valuation has surged back to new highs. Those in the bullish camp say the 19% decline in the S&P 500 between February and April's low priced in enough risk to set the stage for persistent gains. Bears argue lofty valuations and a sputtering economy put stocks at risk of a reckoning. Many Wall Street pros, including popular veteran trader Mark Minervini, have offered their opinions recently. Minervini was mentored by legendary stock picker William O'Neil and was featured in the "Market Wizards" book series for his ability to profit from good and bad tapes. Recently, Minervini delivered a candid message about the stock market, and given his experience, considering what he has to say may be smart. What will happen to the economy next because of tariffs is debatable. Tariff proponents believe that they're the best way to strong-arm a return of manufacturing to America, and the risk of them igniting inflation is overblown. Opponents think tariffs weigh on already cash-strapped consumers, crimping economic activity and slowing business spending while C-suites await trade deal clarity. The reality may wind up landing somewhere in the middle. If so, an uptick in unemployment, stalled inflation progress, and cuts to GDP forecasts could be in the already seeing some worrisome signs. While the unemployment rate is relatively healthy at just 4.1%, it has risen from 3.4% in 2023. Further, over 696,000 people have been laid off year-to-date through May, up 80% year over year, according to Challenger, Gray, & Christmas. The most hawkish Federal Reserve interest rate hikes since former Fed Chair Paul Volcker battled runaway inflation in the early 1980s have contributed to the weakening job markets. The Fed's current Chair, Jerome Powell, raised interest rates by 5% in 2022 and 2023, wrestling CPI inflation down below 3% from 8% in 2022. The drop in inflation is welcome, but there has been limited progress recently. Core Personal Consumption Expenditures (PCE) inflation was 2.7% in May, matching January's reading. Stalled inflation progress may increase the risk that tariffs cause prices to swell again, putting the Federal Reserve in a bind. The Federal Reserve's dual mandate is low inflation and low unemployment, two often contrary goals. When the Fed raises rates, it slows inflation but increases unemployment. When it cuts rates, it lowers unemployment but accelerates inflation. Late last year, the Fed switched from rate hikes to rate cuts, lowering its Fed Funds Rate by 1% to support the job market. However, sticky inflation and tariff uncertainty have since moved the Fed to the sidelines, which is problematic for stocks because higher rates drag on profitability and reduce personal and business spending. In June, the Fed cut its GDP estimate for this year to 1.4%, down from 1.7% in March, and meaningfully below the 2.8% growth notched in 2024. If Powell leaves rates unchanged and the economy gets worse, Congress may not be able to help. Fiscal policy is hamstrung by a mountainous deficit and soaring debt pile, particularly following the passage of the One Big Beautiful Bill Act tax deficit is already above $1.8 trillion, accounting for 6.4% of gross domestic product, and total public debt outstanding is roughly 122% of GDP, far north of the 75% level witnessed during 2008's Great Recession. The CBO estimates that the One Big Beautiful Bill Act will increase national debt by $2.4 trillion through 2034. While this backdrop threatens revenue and earnings growth, the stock market's record-setting run suggests investors think any economic dip will be temporary. Mark Minervini has been trading stocks for nearly 40 years. A technical analyst, Minervini cut his teeth learning from William O'Neil, the veteran Wall Street stock picker likely best known as the founder of Investor's Business Daily. Minervini won the U.S. Investing Championship in 2021 with a remarkable 334.8% return, a record. He also won the title in 1997 with a 155% return. More experts: Fed official sends strong message about interest-rate cuts Billionaire fund manager sends surprising message on trade deficit Hedge-fund manager sees U.S. becoming Greece Since he's a technician, Minervini uses price action to inform his buy and sell decisions. While the rally since April has been rewarding, he has noticed some trouble under the hood that could give active investors pause. "If you are a breakout trader using tight stops — even though the indexes have ripped higher — you have likely experienced a low batting average," wrote Minervini on X. Minervini is a rules-based trader who limits losses by using tight stop-loss orders. Stops can protect your downside, but during periods of volatility, they can trigger more often than usual, reducing your winning percentage. "The frequent occurrence of squats and outright failures continues to dominate as a theme around breakout levels, clearly signaling that conditions remain challenging and volatile around key risk levels," wrote Minervini. "These failed breakouts reveal persistent overhead supply and insufficient follow-through from institutional buyers, underscoring a risk off market with regard to broad-based participation." Minervini prefers to buy stocks as they rise, believing winners will continue to win. The failure of breakout stocks to follow through suggests to him that institutional investors aren't willing to press the accelerator, making it challenging to profit big from trading stocks. "I remain an active participant and careful observer, adjusting day by day and ensuring risk management remains my top priority," wrote Minervini. "As far as breakout stocks are concerned, this is NOT yet an Easy Dollar environment. For the most part, we are still fighting for pennies."Veteran trader has surprising message on stocks first appeared on TheStreet on Jul 14, 2025 This story was originally reported by TheStreet on Jul 14, 2025, where it first appeared. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
